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Hedgehog Signaling Modulates 
Interleukin-33-Dependent Extrahepatic 
Bile Duct Cell Proliferation in Mice
Nataliya Razumilava,1 Junya Shiota,1 Nureen H. Mohamad Zaki,1 Ramon Ocadiz-Ruiz,1 Christine M. Cieslak,1 Kais Zakharia,1 
Benjamin L. Allen,2 Gregory J. Gores,3 Linda C. Samuelson,1,4 and Juanita L. Merchant1,4
Hedgehog (HH) signaling participates in hepatobiliary repair after injury and is activated in patients with cholan-
giopathies. Cholangiopathies are associated with bile duct (BD) hyperplasia, including expansion of peribiliary 
glands, the niche for biliary progenitor cells. The inf lammation-associated cytokine interleukin (IL)-33 is also up-
regulated in cholangiopathies, including cholangiocarcinoma. We hypothesized that HH signaling synergizes with 
IL-33 in acute inf lammation-induced BD hyperplasia. We measured extrahepatic BD (EHBD) thickness and cell 
proliferation with and without an IL-33 challenge in wild-type mice, mice overexpressing Sonic HH (pCMV-Shh), 
and mice with loss of the HH pathway effector glioma-associated oncogene 1 (Gli1lacZ/lacZ). LacZ reporter mice were 
used to map the expression of HH effector genes in mouse EHBDs. An EHBD organoid (BDO) system was devel-
oped to study biliary progenitor cells in vitro. EHBDs from the HH overexpressing pCMV-Shh mice showed in-
creased epithelial cell proliferation and hyperplasia when challenged with IL-33. In Gli1lacZ/lacZ mice, we observed a 
decreased proliferative response to IL-33 and decreased expression of Il6. The HH ligands Shh and Indian HH 
(Ihh) were expressed in epithelial cells, whereas the transcriptional effectors Gli1, Gli2, and Gli3 and the HH recep-
tor Patched1 (Ptch1) were expressed in stromal cells, as assessed by in situ hybridization and lacZ reporter mice. 
Although BDO cells lacked canonical HH signaling, they expressed the IL-33 receptor suppression of tumorigenic-
ity 2. Accordingly, IL-33 treatment directly induced BDO cell proliferation in a nuclear factor κB-dependent man-
ner. Conclusion: HH ligand overexpression enhances EHBD epithelial cell proliferation induced by IL-33. This 
proproliferative synergism of HH and IL-33 involves crosstalk between HH ligand-producing epithelial cells and 
HH-responding stromal cells. (Hepatology Communications 2019;3:277-292).
The Hedgehog (HH) pathway plays a role in hepatobiliary inflammation and injury-re-lated cancers. HH signaling involves Sonic hedgehog (SHH) and Indian hedgehog (IHH) ligands, the receptor Patched-1 (PTCH1), and their transcriptional effectors glioma-associated oncogene 
Abbreviations: ANOVA, analysis of variance; BD, bile duct; BDO, bile duct organoid; BEC, biliary epithelial cell; BrdU, 5-bromo-2′-
deoxyuridine; CK19, cytokeratin 19; DAPI, 4′,6-diamidino-2-phenylindole; EdU, 5-ethynyl-2′-deoxyuridine; EHBD, extrahepatic bile duct; 
GLI, glioma-associated oncogene; H&E, hematoxylin and eosin; HH, hedgehog; Hprt, hypoxanthine guanine phosphoribosyl transferase; IHH, 
Indian hedgehog; IL, interleukin; IL-6R, interleukin 6 receptor; mRNA, messenger RNA; NF-κB, nuclear factor κB; PBG, peribiliary gland; PBS, 
phosphate-buffered saline; pCMV, promoter for cytomegalovirus; PFA, paraformaldehyde; PTCH1, Patched1; QNZ, N4-[2-(4-phenoxyphenyl)
ethyl]-4,6-quinazolinediamine; qPCR, quantitative real-time polymerase chain reaction; RT, room temperature; SHH, Sonic hedgehog; ST2, 
suppression of tumorigenicity 2; Veh, vehicle; WT, wild type.
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1 (GLI1), GLI2, and GLI3.(1) In the canonical HH 
pathway, cells expressing HH ligand signal to stromal 
cells expressing PTCH1 and GLIs in a variety of gas-
trointestinal tissues.(2-4) In the liver, HH ligands are 
expressed in both epithelial cells and myofibroblasts 
after injury, and HH signaling is responsible for the 
“reactive” phenotype of injured cholangiocytes.(5,6) 
Prior studies, including from our group, suggest that 
HH signaling contributes to the initiation and pro-
gression of cholangiocarcinoma.(7,8) However, most 
studies describing HH signaling in hepatobiliary 
pathology have focused on hepatocytes, intrahepatic 
bile ducts (BDs), and fully developed cancer. This 
work focuses on the effects of activated HH signaling 
on extrahepatic BDs (EHBDs) in acute inflammation.
Cholangiopathies represent a group of chronic 
progressive diseases affecting biliary epithelial cells 
(BECs). Cholangiopathies, which include primary 
sclerosing cholangitis and cholangiocarcinoma, are 
associated with inflammation and fibrosis.(9) Peribiliary 
glands (PBGs) are a specialized BEC compartment 
that contains biliary progenitor cells and participates in 
the maintenance and repair of large BDs.(10,11) PBGs 
contain mature and immature cell types and prolifer-
ate in response to BD injury in experimental mouse 
models of biliary atresia and BD obstruction.(10) In 
humans, PBG hyperplasia is observed in numerous 
hepatobiliary pathologies, including cholangitis, cir-
rhosis, and hepatic necrosis, likely representing a com-
pensatory mechanism after biliary injury to replace 
damaged BD epithelium.(12) In patients with primary 
sclerosing cholangitis, increased HH signaling is asso-
ciated with hyperplastic PBGs, dysplastic BD lesions, 
and advanced fibrosis.(13) The mechanisms underlying 
HH regulation of EHBD as well as BEC and PBG 
epithelial hyperplasia have not been well described.
In children with biliary atresia, messenger RNA 
(mRNA) expression of the inflammatory cytokine 
interleukin-33 (Il33) and its receptor suppression of 
tumorigenicity 2 (St2) is increased in the liver and 
IL-33 is increased in serum.(14,15) Overexpression of 
IL-33 was described in patients with inflammatory 
cholangiopathies,(16) including hepatobiliary parasitic 
infection clonorchiasis(17) and visceral leishmaniasis,(18) 
and viral hepatitis B(19) and C.(20) The pro-oncogenic 
effect of IL-33 was recently described in a mouse 
model of cholangiocarcinoma, where biliary injury-in-
duced IL-33 cooperated with Kirsten rat sarcoma viral 
oncogene and transforming growth factor βR2 muta-
tions in the development of cholangiocarcinoma origi-
nating from PBGs.(21) Moreover, it was recently shown 
that IL-33 is a potent biliary mitogen, and IL-33-
mediated proliferation of cholangiocytes was found to 
occur in a paracrine manner through IL-13 secretion 
from nearby type 2 innate lymphoid cells respond-
ing to IL-33.(15) Furthermore, when coupled with the 
oncogenes AKT and yes-associated protein, IL-33 pro-
motes cholangiocarcinoma in mouse, which involves an 
IL-6-sensitive mechanism.(22) In addition to IL-6 reg-
ulation by IL-33, HH signaling and specifically GLI1 
were reported to modulate IL-6 expression in pancre-
atic cancer and stomach preneoplastic lesions.(2,23)
These studies suggest a potential synergism 
between cell survival pathways and inflammation- 
induced cytokines in cholangiocyte proliferation. In 
this study, we tested whether activated HH ligand 
signaling accelerates epithelial cell proliferation in 
EHBDs after an inflammatory challenge with IL-33.
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All mouse experiments were approved by the 
University of Michigan’s Institutional Animal Care and 
Use Committee. Transgenic Shh mice (promoter for 
cytomegalovirus [pCVM]-Shh) and Gli1lacZ/lacZ mice 
have been described.(2,4) The Gli1lacZ./+ and Gli1lacZ./lacZ 
mice contain a knock-in lacZ, encoding a nuclear- 
localized β-galactosidase, into exon 2 of the mouse 
Gli1 gene, producing a null allele.(24,25) The pCMV-
Shh; Gli1lacZ/+ and pCMV-Shh; Gli1lacZ/lacZ mice were 
generated by crossing pCMV-Shh and Gli1lacZ/lacZ mice. 
The Gli2lacZ/+, Gli3lacZ/+, and Ptch1lacZ/+ reporter mice 
have been described.(26-29) All lacZ reporter mice were 
maintained on a mixed C57BL/6J; 129S4/SvJaeJ back-
ground. Mice were housed in a specific pathogen-free 
environment with a 12-hour:12-hour light–dark cycle 
in ventilated caging and provided Enviro-Dri absor-
bent, cotton squares, or cardboard tubing as enrich-
ment. Animals were provided with free access to 
food (5L0D; Purina LabDiet, St Louis, MO) and 
water. Recombinant mouse carrier free IL-33 (R&D 
Systems, Minneapolis, MN) was reconstituted at 1 
μg/100 μL in sterile phosphate-buffered saline (PBS). 
During the light cycle, adult male and female mice 
were given intraperitoneal injections of either PBS 
(100 μL) or IL-33 (1 μg) daily for 4 days, and tis-
sues were isolated on day 5. Animals were euthanized 
during the light cycle with isoflurane combined with 
the removal of a vital organ according to institutional 
guidelines. Experimental replicates were sex and age 
matched as well as littermate matched when possible.
Human samples
Human EHBD tissue from cholangiocarci-
noma and adjacent noncancerous BD was collected 
with the approval of the University of Michigan’s 
Institutional Review Board according to the prin-
ciples embodied in the Declaration of Helsinki. 
Paraffin-embedded tissue was sectioned at 4 μm for 
further studies.
immunoHistoCHemistRy
Mouse EHBDs were isolated and fixed in 10% for-
malin overnight at 4°C and then transferred to PBS 
before paraffin embedding. Human and mouse tissue 
sections (4 μm) were deparaffinized and rehydrated 
in serial xylene and alcohol dilutions and incubated 
in boiling citrate buffer (10 mM, pH 6) for 30 min-
utes for antigen retrieval. After antigen retrieval, slides 
were incubated in a 1% bovine serum albumin/5% 
fetal bovine serum/0.1% Triton X-100–PBS block-
ing solution for 1 hour at room temperature (RT). 
Primary and secondary antibodies (Table 1) were 
diluted in the blocking solution. Tissue was incu-
bated in primary antibodies overnight at 4°C and sec-
ondary antibodies for 1 hour at RT. ProLong Gold 
antifade reagent with 4′,6-diamidino-2-phenylindole 
(DAPI) (Life Technologies, Waltham, MA) was used 
for nuclear counterstaining. Eosin (Thermo Fisher 
Scientific) was used for cytoplasmic staining, hema-
toxylin (Thermo Fisher Scientific) was used as a 
nuclear counterstain, and Permount (Thermo Fisher 
Scientific) was used as a mounting medium for hema-
toxylin and eosin (H&E) staining of deparaffinized 
and rehydrated slides. Images were taken on Olympus 
BX53 and Nikon Eclipse E800 microscopes (Tokyo, 
Japan).
HistologiCal stains
For X-gal staining, mouse EHBD was dissected, 
washed in ice-cold PBS, and fixed in cold 4% para-
formaldehyde (PFA)-PBS for 1 hour before being 
taBle 1. antiBoDy list
Target Primary Antibody Secondary Antibody
ST2 Rabbit, 1:200; ProSci (3363) Biotinylated donkey, ImmunoResearch (712-065-153)
BrdU Sheep, 1:200; Abcam (AB2284) Alexa Fluor 594-Streptavidin, Invitrogen (S11227)
CK19 Rabbit; 1:250; Abcam (AB53119) Alexa Fluor 488-labeled donkey IgG (H+L), Invitrogen (A21206)
IL-6Rα
Rabbit; 1:200; Santa Cruz (SC661) Biotinylated donkey, ImmunoResearch (712-065-153)
IL-33 (human) Goat; 1:20; R&D Systems (AF3625) Biotinylated donkey, Abcam (AB6884)
Abbreviation: H, heavy chain; IgG, immunoglobulin G; L, light chain.
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washed in X-gal wash buffer (1 M MgCl2, 2% NP-40, 
0.1 M sodium phosphate buffer pH 7.3) 3 times at 
RT on a rocker. Tissue was then stained overnight at 
37°C in the dark with 1 mg/mL of X-gal substrate 
(Roche, Basel, Switzerland) in 5 mM K3Fe(CN)6, 
5 mM K4Fe(CN)6 · 3H2O, 2 mM MgCl2, 0.02% 
NP-40, and 0.1% deoxycholate buffer. After staining, 
samples were washed for 30 minutes, postfixed in 4% 
PFA at 4°C overnight, paraffin embedded, sectioned 
at 4 μm, deparaffinized, counterstained with Nuclear 
Fast Red (Sigma-Aldrich, St Louis, MO) for 30 min-
utes, rinsed in tap water, dehydrated in alcohol dilu-
tions, and mounted with Permount.
IN SITU HyBRiDiZation
Mouse EHBD formalin-fixed paraffin-embedded 
sections (5 μm) were deparaffinized and rehydrated in 
Histoclear (National Diagnostics, Atlanta, GA) and 
100% ethanol, followed by 10 minutes of incubation 
in H2O2 (RNAscope Pretreatment Reagents, catalog 
#322330; ACD, Newark, CA). Next, slides were incu-
bated in RNAScope Target Retrieval Reagent (catalog 
#322000; ACD) for 15 minutes at 95°C, rinsed with 
water and 100% ethanol, and treated with RNAScope 
Protease Plus (ACD) for 30 minutes at 40°C. Slides 
were then incubated with RNAScope probes (nega-
tive control [catalog #310043; ACD], Mm-Shh [cat-
alog #314361; ACD], Mm-Ihh [catalog #413091; 
ACD], or Mm-Gli1 [catalog #311001; ACD]) for 
2 hours, with signal amplification using RNAscope 
2.5 HD Detection Reagent (ACD) for 60 minutes 
at 40°C with washes using RNAscope Wash Buffer 
(ACD). Slides were incubated with 3,3′-diaminoben-
zidine for 10 minutes, counterstained with 1:8 Harris’ 
hematoxylin (Thermo Fisher Scientific), dehydrated 
in graded ethanol and Histoclear, and mounted with 
Permount.
BiliaRy pRoliFeRation
Proliferating cells were labeled by 5-bromo-2′-de-
oxyuridine (BrdU) incorporation (50 mg/kg intra-
peritoneally 2 hours before tissue collection). The 
PBG and BEC areas were identified by cytokeratin 
19 (CK19) immunostaining. Epithelial versus stromal 
cell proliferation was measured using ImageJ software 
(National Institutes of Health, Bethesda, MD) by an 
author blinded to experimental conditions.
moRpHometRiCs
Each EHBD section was analyzed for BD wall 
thickness (excluding lumen) at three points 100 µm 
apart. Only sections with well-aligned BD lumen and 
wall were used for analysis. Organoid growth was 
monitored by taking pictures with an inverted Leica 
DM IRB microscope (Wetzlar, Germany) using an 
Olympus DP7 (Tokyo, Japan) camera. The area occu-
pied by organoids was measured with ImageJ software.
Quantitation oF sHH liganD
Blood was collected by cardiac puncture, and serum 
was isolated. SHH ligand levels were measured with 
a spectrophotometric enzyme-linked immunosorbent 
assay kit following the manufacturer’s instructions 
(Sigma-Aldrich). Absorbance was measured at 450 nm 
using a VICTOR3 microplate reader (PerkinEimer, 
Inc., Waltham, MA).
mouse BD oRganoiD CultuRe
EHBD was isolated from adult mice and dissoci-
ated in Accutase (STEMCELL, Cambridge, MA) at 
37°C for 15 minutes, followed by filtration through 
a 70-µm strainer (BD Bioscience, San Jose, CA) and 
centrifugation at 300g for 5 minutes. Cells were resus-
pended in Matrigel (Corning, Tewksbury, MA) and 
plated in prewarmed 12- or 24-well plates, followed 
by overlying with 300 or 600 µL culture media (50% 
L-WRN [CRL-3276; ATCC, Manassas, VA] con-
ditioned media,(30) 1X penicillin–streptomycin, 1X 
GlutaMAX, 10 mM 4-(2-hydroxyethyl)-1-pipera-
zine ethanesulfonic acid, 1X Fungizone, 1X gentami-
cin, 1X B27, and 1X N2 [Thermo Fisher Scientific] 
in advanced Dulbecco’s modified Eagle’s medium/
F12 [Invitrogen; Carlsbad, CA]). Fibroblast growth 
factor 10 (100 ng/mL; PeproTech, Rocky Hill, NJ) 
and epithelial growth factor (50 ng/mL; Invitrogen) 
were added to the culture media for the first 3 days. 
BD organoids (BDOs) were passaged every 7 to 10 
days by mechanically dissociating organoids with a 
25-gauge needle and resuspending them in Matrigel 
at 1:3 to 1:4 ratios. BDO growth and proliferation 
were measured after administration of recombinant 
IL-33 (100 ng/mL; R&D Systems) or nuclear factor 
κB (NF-κB) inhibitor N4-[2-(4-phenoxyphenyl)eth-
yl]-4,6-quinazolinediamine (QNZ; 1 µM, pretreat-
ment for 1 hour; Cayman Chemical, Ann Arbor, MI).




EHBD was isolated and placed into RNAlater 
(Qiagen, Hilden, Germany). Tissue was transferred 
to RPE buffer (RNeasy Micro Kit; Qiagen) and 
homogenized using a bead mill homogenizer (VWR, 
Radnor, PA). Total RNA was isolated from whole 
EHBD tissue or organoids after deoxyribonuclease 
I digestion (Qiagen) using an RNeasy Mini Kit or 
RNeasy Micro Kit (Qiagen). Complementary DNA 
(cDNA) was generated from 500 ng total RNA using 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA). Quantitative real-time polymerase chain reac-
tion (qPCR) was performed in duplicate reactions 
of 20 μL total volume using 100 μM of forward 
and reverse primers (Table 2), 1 μL SYBR Green I 
nucleic acid stain (Lonza, Rockland, ME), and 0.1 μL 
platinum Taq DNA polymerase (Invitrogen) using a 
CFX96 real-time thermocycler (C1000; Bio-Rad). 
Target gene expression was normalized to hypoxan-
thine guanine phosphoribosyl transferase (Hprt) con-
trol mRNA abundance.
Cell lines
The L-WRN (CRL-3276) cell line(30) was pur-
chased from ATCC on November 6, 2015. The 
third and fourth passages were used to generate 
conditioned media for organoid culture. The myco-
plasma detection test (ATCC) was performed on all 
cultures before experiments (last check on May 18, 
2018).
oRganoiD pRoliFeRation
BDOs were incubated in 5-ethynyl-2′-deoxy-
uridine (EdU) (10 µM for 9 hours; Thermo Fisher 
Scientific), washed with PBS, and fixed with 4% PFA 
for 10 minutes at RT. After washing with PBS and 
permeabilization with 0.5% PBS–Triton X-100 for 20 
minutes, BDOs were incubated in the EdU reaction 
cocktail from a Click-iT Plus EdU kit (Thermo Fisher 
Scientific). BDOs were then washed, resuspended in 
ice-cold PBS, placed on a slide, and mounted with 
ProLong Gold with DAPI (Life Technologies). A 
Nikon Eclipse E800 microscope (Nikon, Tokyo, 
Japan) was used to take images.
statistiCal analysis
GraphPad Prism 7 (La Jolla, CA) was used for 
one-way analysis of variance (ANOVA) and unpaired 
Student t test statistical analyses. Quantitative val-
ues were expressed as actual numbers (mRNA 
expression, serum SHH expression, BD thickness 
taBle 2. pRimeR list
Gene Accession Number Primer Sequence Product Size
Hprt NM_013556 Forward 5′-AACTTGCGCTCATCTTAGGCTTTG-3′ 173 bp
Reverse 5′-AGGACCTCTCGAAGTGTTGGATAC-3′
Shh NM_009170 Forward 5′-TCATCACAGAGATGGCCAAG-3′ 122 bp
Reverse 5′-GGAACTCACCCCCAATTACA-3′
Ihh NM_010544 Forward 5′-TGACAGAGATGGCCAGTGAG-3′ 119 bp
Reverse 5′-AGAGCTCACCCCCAACTACA-3′
Gli1 NM_010296 Forward 5′-TATGTCAGGGTCCCAGGGTTATG-3′ 110 bp
Reverse 5′-GAGCCCGCTTCTTAGTCAGTTTG-3′
Gli2 NM_001081125 Forward 5′-CCATTATGACCCTCACTCTGTC-3′ 102 bp
Reverse 5′-GGGTGTGGAGAAAGTCGTATC-3′
Ptch1 NM_008957 Forward 5′-CTGCTGTGGTGGTGGTATTC-3′ 120 bp
Reverse 5′-GGCTTGTGAAACAGCAGAAA-3′
St2 NM_001025602 Forward 5′-ATTCAGGGGACCATCAAGTG-3′ 117 bp
Reverse 5′-CGTCTTGGAGGCTCTTTCTG-3′
Il-6 NM_031168.2 Forward 5’-TTCCATCCAGTTGCCTTCTTGG-3’ 175 bp
Reverse 5’-TTCTCATTTCCACGATTTCCCAG-3’
Abbreviation: bp, base pair.
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or area) and compared with the baseline (wild-type 
[WT] animal or vehicle [Veh]) where applicable. 
Significance was set at P < 0.05. Results are pre-
sented as mean ± SEM.
Results
HH signals to stRomal Cells 
in eHBDs
We examined the cellular basis for HH signal-
ing in EHBD (Fig. 1A) to identify HH-responsive 
cells expressing the general HH pathway compo-
nents.(31,32) Using Gli1lacZ/+, Gli2 lacZ/+, Gli3lacZ/+, 
and PtchlacZ/+ reporter mice, we identified putative 
sites of active HH response in mouse EHBDs (i.e., 
Gli1-expressing and Ptch1-expressing cells) as well as 
those sites that are competent to transduce HH sig-
nals through expression of the GLI transcriptional 
effectors (i.e., Gli-expressing cells). As expected, 
WT mice lacked β-galactosidase activity (Fig. 1B). 
HH target gene expression was observed in stro-
mal cells in Gli1lacZ/+ and PtchlacZ/+ mice (Fig. 1C,F); 
similar stromal expression was noted in Gli2lacZ/+ and 
Gli3lacZ/+ mice (Fig. 1D,E). We tested WT mouse 
EHBDs for mRNA abundance of the HH ligands 
Shh and Ihh. Although mouse EHBDs lacked detect-
able Shh expression at baseline, they readily expressed 
Ihh mRNA (Fig. 1G). These findings indicate that 
EHBD stromal cells are HH-signaling cells and 
IHH is the dominant HH ligand in EHBDs.
pCMV-Shh anD Gli1lacZ/lacZ miCe 
moDel CHRoniC HH liganD 
oVeReXpRession anD gli1 
inHiBition in eHBDs
We previously reported the use of genetically engi-
neered murine models of HH ligand overexpression 
(pCMV-Shh) and the loss of the transcriptional acti-
vator Gli1 (GlilacZ/lacZ) to investigate the consequences 
of modulating HH signaling on Helicobacter pylori-in-
duced stomach metaplasia.(2,4) We took advantage of 
these mouse models to examine the contribution of 
HH signaling in mouse EHBDs. We identified the 
site of HH ligands and effector Gli1 expression in 
EHBDs of pCMV-Shh mice by in situ hybridization 
(Fig. 2B-D). EHBDs from WT mice did not express 
Shh mRNA (Fig. 2A), consistent with the absence 
of detectable Shh mRNA expression in WT mouse 
EHBDs by qPCR (Fig. 1G). In pCMV-Shh mice, Shh 
mRNA and Ihh mRNA were expressed and localized 
in epithelial cells (Fig. 2B,C). Consistent with findings 
in Gli1lacZ/+ mice, Gli1 mRNA was localized in stromal 
cells in EHBDs of pCMV-Shh (Fig. 2D). Additionally, 
GLI1 was stromal in pCMV-Shh; Gli1lacZ./+ and pCMV-
Shh; Gli1lacZ./lacZ mice (Fig. 2E,F). Further, pCMV-Shh 
mice had an increased level of circulating SHH ligand 
in serum compared with WT and Gli1lacZ/lacZ mice 
(Fig. 2G). Gli1, Gli2, and Ptch1 mRNA abundance in 
pCMV-Shh mice compared with WT and Gli1lacZ/lacZ 
mice was significantly increased (Fig. 2H-J). Thus, we 
used the pCMV-Shh mouse model to study the con-
sequences of increased chronic HH pathway activity 
and Gli1lacZ/lacZ mice to study decreased canonical HH 
pathway activity in EHBD stroma in vivo.
HH oVeReXpRession ampliFies 
il-33-inDuCeD epitHelial Cell 
pRoliFeRation IN VIVO
In chronic progressive fibroproliferative disorders, 
such as primary sclerosing cholangitis, chronic injury 
is associated with up-regulation of inflammatory 
cytokines.(33) Cholangiocarcinoma, which frequently 
complicates cholangiopathies, is associated with up-reg-
ulation of HH signaling and also cytokines IL-33 and 
IL-6.(7,22,34) Thus, we examined human EHBD chol-
angiocarcinoma and adjacent noncancerous tissue for 
expression of inflammatory cytokines with immunohis-
tochemistry. We demonstrated that IL-33, which is an 
alarmin and potent biliary mitogen,(15,21) was expressed 
in noncancerous EHBD and was overexpressed in 
cholangiocarcinoma (Fig. 3A). Further, normal adjacent 
bile duct and EHBD cholangiocarcinoma cells strongly 
expressed the IL-6 receptor (IL-6R) (Fig. 3B).
We tested the HH mouse models to determine 
whether increased HH signaling synergizes with 
inflammatory cytokines to promote cell proliferation. 
We showed that mouse EHBDs express the IL-33 
receptor ST2, which is primarily localized in epithe-
lial cells at baseline and in both epithelial and stromal 
cells after IL-33 treatment (Fig. 4A). We treated the 
pCMV-Shh and Gli1lacZ/lacZ mouse models with IL-33 
(Fig. 4B, schema). We examined EHBDs of WT, 
pCMV-Shh, and Gli1lacZ/lacZ mice macroscopically and 
histologically and observed no gross morphological 
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Fig. 1. HH signaling receptive cells are located in the EHBD stroma. Mouse EHBDs were isolated from WT and reporter Gli1lacZ/+, 
Gli2lacZ/+, Gli3lacZ/+, and Ptch1lacZ/+ mice and stained by (A) H&E and (B-F) for β-galactosidase activity (asterisks, BD lumen; arrows, 
epithelial cells; arrowheads, stromal cells; scale bars, 50 µm) (representative images of two to five samples per genotype). (G) Total 
RNA was isolated from EHBDs of WT mice and analyzed for mRNA expression by qPCR of Shh and Ihh referenced to Hprt (n = 15-16 
animals per group). Results are expressed as mean ± SEM. Abbreviation: X-gal, bromochloroindoxyl galactoside.
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Fig. 2. pCMV-Shh and Gli1lacZ/lacZ mice model chronic HH overexpression and inhibition in EHBDs. EHBDs from WT, pCMV-
Shh, and Gli1lacZ/lacZ mice were studied for expression of HH ligands and signaling targets. (A-D) We analyzed EHBDs from WT and 
pCMV-Shh mice with in situ hybridization (RNAscope) for (A,B) expression of Shh mRNA (arrows) and EHBDs from pCMV-Shh 
mice and for (C) expression of Ihh mRNA and (D) Gli1 mRNA (representative images of two samples). (E,F) Gli1 expression was also 
studied by immunofluorescence for β-galactosidase (red; arrows) in pCMV-Shh; Gli1lacZ/+ and pCMV-Shh; Gli1lacZ/lacZ mice. Cell nuclei 
were marked with DAPI (blue; representative images of one and two samples, respectively; arrows, epithelial cells; arrowheads, stromal 
cells; asterisks, lumen; scale bars, 20 µm). (G) Serum level of the SHH ligand was measured by enzyme-linked immunosorbent assay in 
WT, pCMV-Shh, and Gli1lacZ/lacZ mice. (H-J) Total RNA was isolated from EHBDs of the WT, pCMV-Shh, and Gli1lacZ/lacZ mice and 
analyzed for mRNA expression by qPCR of (H) Gli1, (I) Gli2, and (J) Ptch1 referenced to Hprt. Results are expressed as mean ± SEM 
(n = 8-19 animals per group; one-way ANOVA); *P < 0.05, **P < 0.01, ****P < 0.0001. Abbreviation: ns, not significant.
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differences between IL-33 and Veh-treated mice (Fig. 
4C,D, upper panels). However, BD thickness, an indi-
cator of hyperplasia, was increased in IL-33-treated 
pCMV-Shh mice compared with WT controls and 
Gli1lacZ/lacZ mice (Fig. 4E), with increased cellularity 
observed by H&E staining (Fig. 4D).
Analysis of BrdU incorporation demonstrated no 
difference in epithelial and stromal cell prolifera-
tion in EHBDs of WT, pCMV-Shh, and Gli1lacZ/lacZ 
Veh-treated mice (Fig. 5A, upper panel; quantified in 
B). As expected, proliferation was very low because 
cholangiocytes are virtually mitotically dormant at 
baseline.(5) IL-33 induced proliferation of both epi-
thelial and stromal cells (Fig. 5A-C). However, HH 
overexpression amplified the proliferative effect of 
IL-33 on epithelial cells but not on stromal cells (Fig. 
5A-C). Further, Gli1 ablation blunted the IL-33-
induced epithelial cell proliferation (Fig. 5A,B). The 
results suggest that IL-33 is the primary driver of 
EHBD cell proliferation and HH signaling enhances 
cytokine-induced epithelial cell proliferation.
il-6 inCRease is assoCiateD 
WitH HH anD il-33 syneRgism
Both HH and IL-33 signaling are associated 
with IL-6 up-regulation in human cholangiopathies. 
Therefore, we hypothesized that IL-6 may contribute 
Fig. 3. Cytokines IL-33 and IL-6 are expressed in human EHBDs. (A,B) Human extrahepatic cholangiocarcinoma and adjacent 
noncancerous tissue were examined for expression of (A) IL-33 and (B) IL-6R by immunohistochemistry (arrows, epithelial cells; 
arrowheads, stromal cells; asterisks, BD lumen; scale bars, 100 µm).
RaZumilaVa et al. Hepatology CommuniCations, February 2019
286
Fig. 4. HH signaling synergizes with IL-33 in EHBD hyperplasia. (A) EHBDs from WT mice treated with either Veh or IL-33 (1 
µg/mouse/day for 4 days; necropsy on day 5) were analyzed by immunohistochemistry for ST2 expression (representative images of 
three samples). (B,C) EHBDs from WT, pCMV-Shh, and Gli1lacZ/lacZ mice treated with either Veh or mitogen IL-33 intraperitoneally, 
as shown in (B) schema, were (C) examined macroscopically (representative photographs; ruler scale, 1 mm) and (D) histologically 
with H&E (scale bars, 20 µm; asterisks, BD lumen). (D) BD wall thickness from immunohistochemistry images was measured using 
ImageJ software and compared among WT, pCMV-Shh, and Gli1lacZ/lacZ mice treated with either Veh or IL-33 (n = 7-11 animals per 
group). Results are expressed as mean ± SEM; one-way ANOVA; *P < 0.05, ***P < 0.001. Abbreviations: i.p., intraperitoneally; ns, not 
significant.
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to the synergistic effect of HH and IL-33 signaling on 
biliary proliferation in EHBDs. We demonstrated that 
IL-33 increases IL-6R expression in epithelial and stro-
mal cells in WT mouse EHBDs (Fig. 6A). Although 
WT and pCMV-Shh mice exhibited similar increases 
in Il6 mRNA expression after IL-33 treatment, Gli1 
ablation blunted the Il6 mRNA response to IL-33lacZlacZ 
(Fig. 6B). These findings suggest that HH signaling is 
important for IL-33-induced Il6 expression.
We next examined the effect of IL-33 on expres-
sion of HH components by immunohistochemistry 
and qPCR. We demonstrated that after treatment 
Fig. 5. HH signaling synergizes with IL-33 to promote biliary cell proliferation. EHBDs from the WT, pCMV-Shh, and Gli1lacZ/lacZ 
mice treated with either Veh or IL-33 (1 µg/mouse/day for 4 days; necropsy on day 5) were analyzed with immunofluorescence for cell 
proliferation. (A) Proliferating cells were labeled by BrdU incorporation (50 mg/kg, intraperitoneally, 2 hours before necropsy) (red). 
Cell nuclei were marked with DAPI (blue) and BECs with CK19 (green; original magnification ×400). (B,C) Proliferating cells were 
quantified in the epithelial (arrows) and stromal (arrowheads) cell compartments with ImageJ software (n = 5-6 animals per group; five 
or more high-power fields per BD; >500 cells/animal). Results are expressed as mean ± SEM; one-way ANOVA; *P < 0.05, **P < 0.01, 
****P < 0.0001. Abbreviation: ns, not significant.
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with IL-33, Gli1 expression remained stromal 
(Supporting Fig. S1A-C). We further showed that 
mRNA abundance of HH components was not sig-
nificantly changed in various IL-33-treated mouse 
strains (Supporting Fig. S1D-H). In particular, Shh 
mRNA still was not expressed in WT and Gli1lacZ/
lacZ mice even after IL-33 treatment (Supporting 
Fig. S1D), whereas Gli1 mRNA expression remained 
undetectable in Gli1lacZ/lacZ mice treated with IL-33 
(Supporting Fig. S1F). Collectively, these data indi-
cated that IL-33 does not have a direct effect on HH 
signaling modulator expression. However, HH signal-
ing and specifically GLI1 primes EHBD for the pro-
liferative response to IL-33.
il-33 inDuCes epitHelial Cell 
pRoliFeRation IN VITRO
To study the direct effect of IL-33 and HH on 
biliary cell proliferation, we examined WT mice-de-
rived BDOs. We examined organoids for mRNA 
abundance of St2 and the HH signaling effector 
Gli1. As expected from the mouse tissue expression 
patterns (cf. Fig. 1), BDOs expressed St2 but lacked 
Gli1 mRNA expression (Fig. 7A). Thus, BDOs, 
which comprise only epithelial cells, do not exhibit 
canonical GLI1-mediated HH signaling. We inves-
tigated the effect of IL-33 on epithelial cell prolif-
eration in BDOs. Consistent with our in vivo data, 
we found that IL-33 stimulated increased BDO 
growth (Fig. 7B,C) through increased epithelial cell 
proliferation, as measured by EdU incorporation 
(Fig. 7D,E). Further, there was no difference in the 
IL-33-induced proliferative response among WT, 
pCMV-Shh, and Gli1lacZ/lacZ mice-derived organoids 
(Supporting Fig. S2A,B). This result is consistent 
with the in vivo observation that HH signaling 
occurs in stromal cells.
To identify the potential mechanism of IL-33-
induced BDO proliferation, we used the NF-κB 
inhibitor QNZ(35) because IL-33 has been reported 
to signal through NF-κB.(36) Pretreatment of BDOs 
with QNZ effectively prevented IL-33-induced BDO 
proliferation (Fig. 7D,E). Together, our findings sug-
gest that IL-33 can directly stimulate epithelial pro-
liferation in an NF-κB-dependent manner and that 
the HH pathway indirectly supports IL-33-driven 
epithelial proliferation through activation of signaling 
in stromal cells.
Discussion
Our current results demonstrate that EHBD 
stromal cells express the HH transcriptional effec-
tors GLI1, GLI2, and GLI3 as well as the recep-
tor PTCH1 and thus appear to be the primary cells 
responding to the HH ligand. They also demon-
strate that HH ligand expression is limited to the 
epithelium and that IHH is the predominant HH 
ligand expressed both under basal conditions and 
after inflammatory challenge with IL-33. We used 
pCMV-Shh mice as a model to study the conse-
quences of HH ligand overexpression in EHBDs 
Fig. 6. IL-33-induced IL-6 expression in mouse EHBDs 
involves Gli1. (A) EHBDs from WT mice were analyzed by 
immunohistochemistry for IL-6R expression after treatment with 
either Veh or recombinant IL-33 intraperitoneally (representative 
images of two samples; asterisks, BD lumen; arrows, epithelial 
cells; arrowheads, stromal cells; scale bars, 10 µm). (B) Total 
RNA was isolated from BDs of the WT, pCMV-Shh, and Gli1lacZ/
lacZ mice treated with either Veh or IL-33 and analyzed for 
mRNA expression by qPCR of Il6 referenced to Hprt. Results are 
expressed as mean ± SEM (n = 5-8 animals per group; one-way 
ANOVA; *P < 0.05).
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because IHH and SHH both signal through the 
same receptor and GLI effectors.(37) Although the 
CMV promoter expressing the Shh transgene should 
be nonspecific, it has been demonstrated to prefer-
entially drive expression in certain cells within dif-
ferent organ systems.(38) For example, expression 
Fig. 7. IL-33-induced BDO cell proliferation in vitro. (A) Total RNA was isolated from the WT mouse-derived organoids and 
analyzed for mRNA expression of St2 and Gli1 (n = 3 organoid lines). (B,C) BDOs were treated with Veh or recombinant IL-33 (100 
ng/mL) for 72 hours (day 3) starting 24 hours after passage of established BDOs and analyzed for growth (n = 6 technical replicates 
per group). (D,E) In a separate experiment, BDOs were treated with either Veh or pretreated for 1 hour with the NF-κB inhibitor 
QNZ (1 µM) and then treated with recombinant IL-33 (100 ng/mL) for 72 hours (day 3) after passaging of established BDOs. BDOs 
were analyzed for proliferation (n = 3 technical replicates per group). (D) The organoids were incubated with EdU for 9 hours to label 
proliferating cells (green) among all BDO cells (cell nuclei, DAPI [blue]; original magnification ×600). (E) ImageJ software was 
used to enumerate proliferating cells. Results are expressed as mean ± SEM; one-way ANOVA (C,E); ***P < 0.001, ****P < 0.0001. 
Abbreviation: D0/D3, day 0/day 3.
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of SHH in pCMV-Shh mice was enriched in gas-
tric chief cells in the stomach.(2) In our genetically 
engineered mouse model of HH ligand overexpres-
sion, Shh and Ihh were localized to epithelial cells. 
Therefore, our observation of HH ligand expression 
in epithelial cells and GLI1 in stromal cells is con-
sistent with HH signaling from epithelial to stromal 
cells as observed in other organ systems, including 
the stomach and intestine.(2,39,40)
Our studies further suggest that increased HH 
signaling alone is insufficient to induce EHBD 
epithelial cell proliferation. However, HH over-
expression augmented the proliferative effect of 
the inflammatory cytokine and alarmin IL-33 
on EHBD epithelial cells but not stromal cells. 
Interestingly, reduction in canonical HH signal-
ing in receptive stromal cells attenuated the IL-33 
effect on epithelial proliferation, indicative that syn-
ergism between HH and IL-33 signaling involves 
GLI1-positive stromal cells. These findings sug-
gest that BECs respond to HH up-regulation dif-
ferentially with no changes in cell proliferation at 
basal conditions and with an enhanced proliferative 
response under inflammatory challenge. However, 
the HH-dependent factor that enhances epithelial 
cell response to IL-33 is unknown.
As both HH and IL-33 pathways are reported to 
signal through IL-6,(23,41,42) we explored the poten-
tial role of IL-6 in the synergism between HH and 
IL-33 signaling in IL-33-induced cell proliferation 
in EHBDs. We demonstrated that IL-33 and IL-6R 
are expressed in human cholangiocarcinoma and adja-
cent normal EHBD tissue. We also demonstrated 
that IL-33 induces expression of Il6, which is in part 
dependent on GLI1-positive stromal cells. Therefore, 
GLI1-expressing stromal cells might be important in 
epithelial cell responses to inflammatory cytokines. It 
is possible that HH ligand overexpression “primes” 
GLI1-positive stromal cells and activates GLI1 gene 
targets, which indirectly affects cytokine signaling in 
EHBD epithelial cells. Alternatively, IL-33 signaling 
primes the epithelial cells to be more responsive to 
HH-dependent stroma-derived factors (Fig. 8).
It was reported that IL-33 promotes cholangiocyte 
proliferation indirectly through type 2 innate lym-
phoid cell IL-13.(15) However, in our biliary organoid 
culture, we demonstrated that IL-33 also can directly 
induce proliferation in biliary progenitor cells. This 
IL-33 proliferative effect on biliary progenitor cells 
is NF-κB dependent. The latter observation is inter-
esting as IL-33 induces cytokine expression through 
NF-κB.(42) In addition, NF-κB activation in cholan-
giocytes exposed to liver fluke Opisthorchis viverrini 
is associated with up-regulation of IL-6 and IL-8,(43) 
and IL-33 overexpression occurs in hepatobiliary par-
asitic infection clonorchiasis(17) and visceral leishman-
iasis.(18) Thus, IL-33 can affect EHBD responses both 
directly and indirectly through regulating another 
cytokine function.
These data have relevance to human diseases as 
IL-6 overexpression was recently described in chol-
angiocarcinomas arising in patients with primary 
sclerosing cholangitis associated with extensive 
PBG hyperplasia.(44) HH signaling up-regulation 
was also reported in patients with primary scleros-
ing cholangitis and PBG hyperplasia.(13) An asso-
ciation between IL-33 and IL-6 has been shown 
in patients with cholangiocarcinoma, where IL-33 
overexpression was observed in cancer involving 
large versus small BDs, and was associated with 
IL-6 overexpression.(34)
In summary, we report a previously unknown 
role for HH signaling in the regulation of EHBD 
homeostasis by promoting context-dependent BEC 
proliferation contributing to EHBD hyperplasia. 
This involves crosstalk between HH ligand-produc-
ing cells and receptive GLI1-positive stromal cells 
(Fig. 8). We also showed that the alarmin IL-33 can 
Fig. 8. Model of HH and IL-33 synergy in IL-33-induced 
EHBD epithelial cell proliferation. IHH is secreted by epithelial 
cells and activates GLI1-positive stromal cells. After EHBD 
injury, IL-33 signals to GLI1-positive stromal and epithelial 
cells through the ST2 receptor. IL-33 signaling involves the 
transcriptional effector NF-κB in epithelial cells. IL-33 induces 
IL-6 expression, which can signal to both epithelial and stromal 
cells. Increased epithelial cell proliferation induced by IL-33 is 
partially HH dependent through a yet uncharacterized stromal 
factor.
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directly induce epithelial cell proliferation. Future 
studies identifying the proliferative signals from 
HH-responding GLI1-positive stromal cells toward 
epithelial cells and the mechanisms of HH signal-
ing and inflammatory cytokine interactions will be 
needed. They could provide insight into how and, 
importantly, when HH and/or cytokine signaling can 
be targeted to prevent EHBD hyperplasia, which can 
be preneoplastic in chronic biliary conditions, such as 
primary sclerosing cholangitis.
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